从普通肝素到磺达肝癸钠——肝素类抗凝药物研发历程精选.pptVIP

  • 15
  • 0
  • 约3.13万字
  • 约 58页
  • 2018-03-04 发布于湖北
  • 举报

从普通肝素到磺达肝癸钠——肝素类抗凝药物研发历程精选.ppt

从普通肝素到磺达肝癸钠——肝素类抗凝药物研发历程精选

* 抗Xa活性对分子量不敏感,抗IIa活性依赖分子量。分子量越大,抗IIa活性越强。 * Permission needed. * Permission needed. * 肝素与PF4结合形成复合体,此复合体再会结合IgG形成了HIT抗体,HIT抗体通过IgG与血小板相结合,从而造成了血小板与血小板之间的聚集。由此引起血小板减少症以及血栓形成。 * Although fondaparinux does not mediate the inhibition of coagulation factors other than factor Xa, it inhibits thrombin generation in a dose-dependent manner, whether triggered via the extrinsic or intrinsic pathway, and in the absence or presence of platelets.1-3 This last finding, which may reflect the lack of sensitivity of fondaparinux to inactivation by platelet-released heparin-neutralising proteins such as plate

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档